Clinical Trials Logo

Amantadine clinical trials

View clinical trials related to Amantadine.

Filter by:
  • None
  • Page 1

NCT ID: NCT04367883 Recruiting - COVID19 Clinical Trials

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Start date: March 1, 2020
Phase:
Study type: Observational

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

NCT ID: NCT03443037 Recruiting - Coma; Prolonged Clinical Trials

Benefits of Amantadine in Patients With Coma State

Start date: March 1, 2016
Phase:
Study type: Observational

The study was a single center observational-prospective study and approved by local ethics committee. Patients in coma state due to traumatic brain injury, cardiac arrest or ischemic stroke who are older than 18 years of age were included in the study. Patients who received amantadine 200mg/day for fourteen days according to ICU protocols decided by primary physician formed the amantadine group, and the rest of the subjects were included in the control group. All patients were evaluated for Glasgow Coma Score, JFK Coma Recovery Scale and Disability Rating Scale once a week for three months.